Patient serum samples from the METEOR trial were tested for the levels of LDL-EVs and their protein content of von Willebrand factor (vWF), serpin C1, and plasminogen X. The METEOR trial sought to determine the effect of rosuvastatin on subclinical atherosclerosis, since patients at risk of CVD with high LDL levels, are often treated with statins. This evidence concerns the gene VWF and atherosclerosis.